ALNOV:EPA
Novacyt SA
0,44 €
0,00%
(0,00) 1 p
19. nov, 17:35:19 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse ALNOV põhistatistika genereerimine…
Ava
0,44 €
Kõrge
0,45 €
Madal
0,44 €
Turu kapit.
33,30 mln
Keskm. maht
136,90 tuh
Maht
0,00
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
37,66 mln
Töötajate arv
228
Ava
0,44 €
Kõrge
0,45 €
Madal
0,44 €
Turu kapit.
33,30 mln
Keskm. maht
136,90 tuh
Maht
0,00
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
37,66 mln
Töötajate arv
228
Uudised
Veebiallikatest ja uudistepartneritelt
Adam Feldman | Substack
·
7 tunni eest
Inside the Federal Litigation of Five S&P 500 Giants
The Motley Fool
·
1 tunni eest
The S&P 500 Just Fell 4 Straight Weeks From a Record High. Here’s Why I’m Buying the Dip.
The Harvard Law School Forum on Corporate Governance
·
13 tunni eest
Board Practices and Composition in the Russell 3000 and S&P 500
Barron's
·
13 tunni eest
S&P 500 Futures Rise in Premarket Trading; Credicorp, Intercorp Finl Svcs Lead
Profiil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Teave üksuse Novacyt SA kohta
TegevjuhtDavid Allmond
Töötajad228
Asutatud3. juuli 2006
Peakontorid-
SektorHealth Care
Valdkond-
Veebisaitnovacyt.com